文献速递造血干细胞移植与细胞治疗

单倍型移植后激素耐药急性GVHD危险因素分析

[Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究纳入85例单倍型造血干细胞移植后发生急性GVHD的成人AML/MDS患者,分析糖皮质激素耐药的危险因素。结果显示明尼苏达危险度积分高危和移植物单个核细胞量≥8.33×10^8/kg是激素耐药急性GVHD的独立危险因素,且激素治疗达CR者22个月总生存率显著优于非CR者。

要点

  • 明尼苏达积分高危和移植物单个核细胞量≥8.33×10^8/kg为激素耐药aGVHD独立危险因素。
  • Ⅲ/Ⅳ度aGVHD及累及2个靶器官者激素治疗CR率显著低于Ⅰ/Ⅱ度及单器官受累者。
  • 激素治疗后达CR者22个月总生存率显著高于非CR者。

核心结论

  • 明尼苏达危险度积分和移植物单个核细胞数可预测haplo-HSCT后糖皮质激素耐药的急性GVHD。

研究设计与样本

  • 回顾性分析2010年1月至2012年12月北京大学血液病研究所接受haplo-HSCT后并发aGVHD的成人AML/MDS患者临床资料,共纳入85例。

主要发现

  • 激素治疗后CR 53例(62.4%)、PR 6例(7.1%)、NR 26例(30.6%)。
  • Ⅰ/Ⅱ度与Ⅲ/Ⅳ度aGVHD的激素治疗CR率分别为66.2%(51/77)与25.0%(2/8)(χ²=3.639,P=0.048)。
  • 累及1个与2个靶器官的aGVHD激素治疗CR率分别为77.4%(48/62)与21.7%(5/23)(χ²=22.157,P<0.001)。
  • 明尼苏达积分标危与高危组激素治疗CR率分别为67.5%(52/77)与12.5%(1/8)(χ²=7.153,P=0.004)。
  • 激素治疗CR组与非CR组移植后22个月总生存率分别为(95.2±3.4)%与(78.6±7.9)%(χ²=5.287,P=0.021)。

关键数值与推荐

  • 多因素分析显示明尼苏达危险度积分高危和移植物单个核细胞量≥8.33×10^8/kg是激素耐药aGVHD的独立危险因素。
  • 明尼苏达积分标危组(77例)与高危组(8例)移植后22个月总生存率分别为(90.3±3.8)%与(75.0±15.3)%(χ²=2.831,P=0.092)。

临床怎么用

  • 对haplo-HSCT后发生aGVHD的患者,可结合明尼苏达危险度积分和移植物单个核细胞量评估激素耐药风险。
  • 对明尼苏达积分高危或移植物单个核细胞量≥8.33×10^8/kg者应警惕激素耐药,及早识别并加强监测。

局限性

  • 回顾性单中心研究,样本量较小(85例),明尼苏达高危组仅8例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the risk factors of steroid resistant acute graft- versus-host disease (aGVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) . Methods: The clinical data of adult patients with acute myeloid leukemia (AML) /Myelodysplastic syndrome (MDS) who developed aGVHD after haplo-HSCT in Peking University Institute of Hematology from January 1st, 2010 to December 31st, 2012 were retrospectively reviewed. Results: A total of 85 patients were enrolled in the study, including 55 males and 30 females, with a median age of 30 (19-67) years. After steroid therapy, there were 53 (62.4%) , 6 (7.1%) and 26 (30.6%) patients achieved complete remission (CR) , partial remission (PR) and non-remission (NR) , respectively. The CR rates of the grade Ⅰ/Ⅱ and Ⅲ/Ⅳ aGVHD by steroid therapy were 66.2% (51/77) vs 25.0% (2/8) (χ(2)=3.639, P=0.048) , respectively. The CR rates of the patients with aGVHD involving 1 target organ and 2 target organs were 77.4% (48/62) vs 21.7% (5/23) (χ(2)=22.157, P<0.001) . The CR rates of patients with standard risk (SR) and high risk (HR) Minnesota risk score was 67.5% (52/77) vs 12.5% (1/8) (χ(2)=7.153, P=0.004) . The mononuclear cells≥8.33×10(8)/kg and the HR Minnesota risk score were independent risk factors for steroid-resistant aGVHD in multivariate analysis. Between Minnesota risk score SR (77 cases) and HR (8 cases) groups, the OS rates at 22 months after transplantation were (90.3±3.8) %vs (75.0±15.3) % (χ(2)=2.831, P=0.092) . After steroid treatment for aGVHD, the OS rates at 22 months in the CR group (53 cases) and non-CR group (32 cases) were (95.2±3.4) %vs (78.6±7.9) % (χ(2)=5.287, P=0.021) respectively. Conclusion: The Minnesota risk score and mononuclear cells count are effective tool for predicting steroid-resistant aGVHD after haplo-HSCT. 目的: 分析单倍型造血干细胞移植(haplo-HSCT)后糖皮质激素耐药急性移植物抗宿主病(GVHD)的危险因素。 方法: 回顾性分析2010年1月至2011年12月在北京大学血液病研究所接受haplo-HSCT后并发急性GVHD的成人急性髓系白血病/骨髓增生异常综合征患者的临床资料。 结果: 共有85例急性GVHD患者纳入研究,男55例,女30例,中位年龄30(19~67)岁。糖皮质激素治疗后达到完全缓解(CR)53例(62.4%),部分缓解(PR)6例(7.1%),未缓解(NR)26例(30.6%)。Ⅰ/Ⅱ、Ⅲ/Ⅳ度急性GVHD组糖皮质激素治疗的CR率分别为66.2%(51/77)、25.0%(2/8)(χ(2)=3.639,P=0.048);累及1个、2个靶器官急性GVHD组糖皮质激素治疗的CR率分别为77.4%(48/62)、21.7%(5/23)(χ(2)=22.157,P<0.001);明尼苏达危险度积分标危、高危组糖皮质激素治疗的CR率分别为67.5%(52/77)、12.5%(1/8)(χ(2)=7.153,P=0.004)。单因素和多因素分析均显示明尼苏达危险度积分高危和移植物单个核细胞量≥8.33×10(8)/kg是发生糖皮质激素耐药急性GVHD的独立危险因素。明尼苏达积分标危组(77例)、高危组(8例)移植后22个月总生存率分别为(90.3±3.8)%、(75.0±15.3)%(χ(2)=2.831,P=0.092);糖皮质激素治疗CR组(53例)、非CR组(32例)移植后22个月总生存率分别为(95.2±3.4)%、(78.6±7.9)%(χ(2)=5.287,P=0.021)。 结论: 明尼苏达危险度积分和移植物单个核细胞数可以预测haplo-HSCT后糖皮质激素耐药的急性GVHD。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu WB, Sun YQ, Zhang XH, et al. [Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135625. doi:10.3760/cma.j.issn.0253-2727.2020.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。